SEC For	m 4 FORM	4		STAT	ES S					ANGE	со	MMISS	SION				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									-	P	OMB Estim	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person <sup>*</sup> McBride John S.					2. Issuer Name and Ticker or Trading Symbol <u>Novus Therapeutics, Inc.</u> [ NVUS ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify				vner
(Last)(First)(Middle)C/O NOVUS THERAPEUTICS, INC.19900 MACARTHUR BLVD., SUITE 550					3. Date of Earliest Transaction (Month/Day/Year) 09/11/2020								below) below)				
(Street) IRVINE	С	A	92612		4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip) able I - Non-	Deriva	tive S	Securitie	es A	cquired, C	Disposed	l of, or	Bene	ficially	Owned				
1. Title of Security (Instr. 3)			2. Transa Date (Month/E			2A. Deemed Execution Dat if any (Month/Day/Ye		Code (In	ion Dispo	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			4 and 5) Securities Beneficiall Owned Fol Reported		Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	V Amou	nt (/	A) or D)	Price	Transactio (Instr. 3 an				(
			Table II - D (e					quired, Di ts, options					wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou Securities Underl Derivative Securi (Instr. 3 and 4)		derlying curity	ing Derivative		per of ve es ially d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	i	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Stock Option (Right to Buy)	\$500	09/11/2020		А		1,167.21		(1)	09/11/2030	Series Convert Preferr Stock	tible red	1,167.21	\$0.00	1,167	7.21	D	

Explanation of Responses:

This option represents a right to purchase a total of 1,167.21 shares of the Issuer's Series X1 Convertible Preferred Stock, which will vest in equal monthly installments over two years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c).
 Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the tsockholders of the Issuer.

Remarks:

/s/ Ryan A. Murr, as attorney-infact for John S. McBride 09/15/2020

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.